Syra Health Marks First Anniversary as a Publicly Traded Company With Strong Successes and Growth
Syra Health Marks First Anniversary as a Publicly Traded Company With Strong Successes and Growth
CARMEL, Ind., Oct. 1, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company powering better health by providing meaningful solutions, is celebrating its first anniversary as a publicly traded company and highlighting its many successes. This milestone not only marks the Company's growth but also reflects its unwavering commitment to transforming healthcare service. As the Company highlights significant achievements over the past year, it remains focused on its mission to become a leader in healthcare solutions, empowering communities and improving health outcomes across the nation.
納斯達克(納斯達克: SYRA)健康科技公司塞拉健康公司("Syra Health"或"公司")是一家通過提供有意義的解決方案實現更好健康的醫療科技公司,正在慶祝其作爲一家上市公司的第一個週年,並突出其許多成功。這個里程碑不僅標誌着公司的增長,也反映了其對改變醫療服務的執着承諾。在公司突出過去一年的重大成就的同時,它專注於成爲醫療解決方案領導者的使命,賦權社區,改善全國的健康結果。
"It's exciting to look back on what the Syra Health team has achieved over the past year since our Nasdaq listing," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We have increased our revenues and are strategically taking actions to reduce operating expenses. We are expanding our impact across various geographies and business units, always with a focus on making a real difference in the communities we serve. By focusing on our high-margin areas, we have not only boosted our profit margins but also continued to invest in innovative solutions that will shape the future of healthcare. Our legacy business unit, Healthcare Workforce, remains the cornerstone that fuels these advancements, allowing us to push boundaries and improve health outcomes every step of the way."
"回顧過去一年自我們在納斯達克上市以來塞拉健康團隊取得的成就令人興奮," 塞拉健康的首席執行官迪皮卡·沃普蘭奇博士表示。"我們增加了收入,並正在採取策略上的行動減少營業費用。我們正在擴大在各個地理區域和業務部門的影響力,始終以在服務的社區中真正產生影響爲重點。通過專注於我們的高毛利潤領域,我們不僅提升了利潤率,還繼續投資於將塑造未來醫療行業的創新解決方案。我們的傳統業務部門——醫療人力資源,仍然是推動這些進步的基石,使我們能夠突破界限,改善健康結果。"
Syra Health's achievements since the Company's 2023 IPO:
塞拉健康自公司2023年首次公開募股以來的成就:
- Achieved record quarterly revenue growth of 47% in Q1 2024 and 101% in Q2 2024 compared to the respective quarters in the previous year
- Enhanced profit margins by concentrating on high-margin business units
- Active contracts in 24 states across the nation
- Subcontractor to prime vendors on two federal contracts with the Defense Health Agency and Health and Human Services, totaling $118 Billion in ceiling value. Monetization will occur upon receipt of task orders
- Continues to secure multiple contract wins across all of the company's business units including recent Healthcare Workforce wins in Delaware, Florida, and Kansas and a contract extension in Washington D.C. with ceiling value up to $4 Million
- Successfully raised $2.1 Million in capital to fund the additional development of Syrenity, our innovative mental health app, along with robust sales and marketing initiatives, and ongoing research and development efforts
- Implementations of several high-profile state government projects are underway
- Strategic restructuring of operations designed to drive cost reductions and enhance operational efficiencies
- Introduced the "Roadmap to Greatness" initiative internally outlining commercial, operational, innovation, and people goals for the company
- 2024年第一季度營收增長47%,第二季度增長101%,與前一年相比
- 通過專注高毛利業務部門增強利潤率
- 全國24個州的活躍合同
- 在國防衛生局和衛生與公衆服務部與兩項聯邦合同上作爲主要供應商的分包商,總額爲1180億美元。在接到任務訂單後將實現貨幣化
- 繼續在該公司所有業務部門中獲得多項合同勝利,包括最近在特拉華州、佛羅里達州和堪薩斯州的醫療人力資源獲勝,並與華盛頓特區續簽合同,上限價值達到400萬美元
- 成功籌集了210萬美元資金,用於資助我們創新的精神健康應用Syrenity的進一步開發,以及強大的銷售和營銷舉措,以及持續的研究和開發工作
- 多個備受關注的州政府項目的實施正在進行中
- 旨在推動降低成本並增強運營效率的戰略性運營重組正在進行中
- 在公司內部推出了"偉大之路"計劃,概述了商業、運營、創新和人員目標
"From a financial standpoint, we have significantly increased our revenues over the past year while actively working to reduce our operating expenses and increase operational efficiencies," said Priya Prasad, CFO, Syra Health. "Our team is dedicated to delivering innovative healthcare solutions, whether through services or technology products. We are committed to improving health and progressing on our journey to profitability."
"從財務角度來看,過去一年我們的營業收入大幅增加,同時積極努力減少營業費用並增加運營效率," Syra Health的CFO Priya Prasad表示。"我們的團隊致力於提供創新的醫療解決方案,無論是通過服務還是技術產品。我們致力於改善健康,並在走向盈利的道路上不斷進步。"
ABOUT SYRA HEALTH
關於SYRA HEALTH
Syra Health is a healthcare technology company powering better health in challenging areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology products. Syra Health's offerings are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit .
希拉健康是一家醫療保健科技公司,以提供創新服務和技術產品爲主,推動在行爲和心理健康、數字健康和群體健康等具有挑戰性的領域的更好健康。希拉健康的提供產品主要圍繞預防、改善訪問和提供實惠的醫療保健。希拉健康向付款人、提供者、生命科學組織、學術機構和政府提供其解決方案。更多信息,請訪問。
FORWARD-LOOKING STATEMENTS
前瞻性聲明
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
本新聞稿中關於未來預期、計劃和前景,以及關於非歷史事實的任何其他事項的陳述,可能構成「前瞻性聲明」。這些聲明包括但不限於關於預期收益使用、公司的運營和業務策略以及公司預期的財務結果的聲明。"預計"、"相信"、"持續"、"可能"、"估計"、"期望"、"打算"、"可能"、"計劃"、"潛在"、"預測"、"項目"、"應該"、"目標"、"將"、"會"等類似表達的詞語旨在識別前瞻性聲明,儘管並非所有前瞻性聲明都包含這些識別詞語。本新聞稿中包含的前瞻性聲明是基於管理層當前的預期,並且可能受到重大風險、不確定性和環境變化的影響。投資者應閱讀我們在2023年12月31日結束的年度10-k表中闡明的風險因素以及提交給證券交易委員會的其他定期報告。本新聞稿中包含的任何前瞻性聲明僅當日有效,並且除非根據聯邦證券法要求,否則公司明確否認更新任何前瞻性聲明,無論是根據新信息、未來事件或其他情況。
Contacts
For Media or Investor Inquiries:
Christine Drury
PR/IR and Marketing Director
Syra Health
463-345-5180
[email protected]
聯繫方式
媒體或投資者查詢:
克莉絲汀·德魯裏
公關/投資關係和市場營銷負責人
Syra Health
463-345-5180
[email protected]
SOURCE Syra Health
來源:Syra Health